WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Monday, September 10, 2018

New high-throughput screening study may open up for future Parkinson's disease therapy

10-Sep-2018 Aarhus University




New screening strategy gives rise to identification of novel inhibitors of α-synuclein aggregation, which may help develop a cure for Parkinson's disease. Here is a graphical overview of the screening of 746,000 compounds for the inhibitory effects.



Parkinson's disease (PD) is the most common movement disorder in the world. PD patients suffer from shaking, rigidity, slowness of movement and have difficulties walking. It is neurodegenerative disease and is caused by the loss of dopaminergic neurons in the brain. 

Currently PD cannot be cured or even halted in its development, but symptoms may be treated to some degree. Probably the single most important cause of PD is the aggregation of the natively unfolded protein α-synuclein (αSN). αSN can form both small oligomeric complexes (αSOs) as well as large fibrillary deposits; the αSOs are thought to be the most toxic species.

 If we can prevent or reduce αSN aggregation we have a good way to halt PD development. So far it has been difficult screen large numbers of compounds to identify potential aggregation inhibitors, since αSN aggregates in a rather irregular and variable fashion; it is also difficult to detect early-stage αSOs.

However, in the new screening strategy, the researchers first developed a smart trick to make αSN aggregate in a more predictable way using the "soap" molecule sodium dodecyl sulfate. To detect the aggregates, they then used Förster Resonance Energy Transfer (FRET), a widely used technique for measuring distances within and between molecules. 

In this way they were able to screen 746,000 compounds for their ability to inhibit αSN aggregation. 

By sifting through the results, they came up with a collection of structurally diverse, novel small compounds that either prevent (inhibitor) or accelerate (proaggregator) αSN aggregation. The six best inhibitors share a common core structure and these compounds all interact with the first part of αSN, called the N-terminal region.
###
The results have just been published in the international journal Cell Chemical Biology:

Martin Kurnik, Cagla Sahin, Camilla Bertel Andersen, Nikolai Lorenzen, Lise Giehm, Hossein Mohammad-Beigi, Christian Moestrup Jessen, Jan Skov Pedersen, Gunna Christiansen, Steen Vang Petersen, Roland Staal, Girija Krishnamurthy, Keith Pitts, Peter H. Reinhart, Frans A.A. Mulder, Scot Mente, Warren D. Hirst and Daniel E. Otzen: Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State.

This work was funded by innovation consortium CureND and Center of Excellence inSPIN - financed by Danish Agency of Science, Technology, and Innovation, Independent Research Fund Denmark, the Danish National Research Foundation as well as Aarhus University Research Foundation.

For further information, please contact
Professor Daniel Otzen
Interdisciplinary Nanoscience Center and Department of Molecular Biology and Genetics dao@inano.au.dk - +45 20725238

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

https://www.eurekalert.org/pub_releases/2018-09/au-nhs091018.php

No comments:

Post a Comment